Trial Profile

TOUR: Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tofacitinib (Primary)
Indications Ulcerative colitis
Focus Therapeutic Use
Acronyms TOUR

Most Recent Events

29 Jan 2024 Status changed from recruiting to discontinued (Futility; recruitment to slow to justify longer study duration).
03 Apr 2023 Results (n=96) published in the Inflammatory Bowel Diseases.
21 Feb 2022 Planned number of patients changed from 100 to 200.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com